Literature DB >> 11145797

The impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitis.

L Drake1, M Prendergast, R Maher, D Breneman, N Korman, Y Satoi, K M Beusterien, I Lawrence.   

Abstract

BACKGROUND: Atopic dermatitis can have detrimental effects on health-related quality of life (QOL).
OBJECTIVE: Our purpose was to examine the QOL impact of tacrolimus ointment in patients with atopic dermatitis.
METHODS: The Dermatology Life Quality Index (DLQI), Children's DLQI (CDLQI), and Toddler QOL Survey were used to assess QOL in adults (16 years or older), children (5-15 years), and toddlers (2-4 years) enrolled in 12-week, randomized, double-blind studies comparing two concentrations of tacrolimus ointment (0.03% and 0.1%) versus vehicle ointment for treatment of atopic dermatitis. QOL was assessed at baseline, week 3, and week 12/early discontinuation.
RESULTS: Of the 985 patients enrolled, 91.5% had evaluable QOL data. Among adults, both tacrolimus ointment groups experienced improved QOL relative to the vehicle control group for all QOL scales (P<.001). Among children and toddlers, both tacrolimus ointment groups demonstrated significant QOL improvements relative to the vehicle control group (P<.05) for all but the Personal Relationships scale in the 0.03% tacrolimus ointment group among children.
CONCLUSION: Tacrolimus ointment is associated with significant QOL benefits in adults, children, and toddlers with atopic dermatitis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11145797     DOI: 10.1067/mjd.2001.109814

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  16 in total

1.  Tacrolimus ointment: advancing the treatment of atopic dermatitis.

Authors:  V S Beltrani
Journal:  Curr Allergy Asthma Rep       Date:  2001-07       Impact factor: 4.806

2.  Validation of expert opinion in identifying comorbidities associated with atopic dermatitis/eczema.

Authors:  Charles N Ellis; Lynn A Drake; Mary M Prendergast; William Abramovits; Mark Boguniewicz; C Ralph Daniel; Mark Lebwohl; Seth R Stevens; Diane L Whitaker-Worth; Kuo B Tong
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 3.  Safety of topical calcineurin inhibitors in atopic dermatitis: evaluation of the evidence.

Authors:  Jonathan M Spergel; Donald Y M Leung
Journal:  Curr Allergy Asthma Rep       Date:  2006-07       Impact factor: 4.806

Review 4.  The economics of topical immunomodulators for the treatment of atopic dermatitis.

Authors:  William Abramovits; Mark Boguniewicz; Amy S Paller; Diane L Whitaker-Worth; Mary M Prendergast; Michael Tokar; Kuo B Tong
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 5.  Tacrolimus ointment: a review of its use in atopic dermatitis and its clinical potential in other inflammatory skin conditions.

Authors:  Dene Simpson; Stuart Noble
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 6.  Eczema.

Authors:  Jochen Schmitt; Christian J Apfelbacher; Carsten Flohr
Journal:  BMJ Clin Evid       Date:  2011-05-17

Review 7.  Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials.

Authors:  Darren M Ashcroft; Paul Dimmock; Ruth Garside; Ken Stein; Hywel C Williams
Journal:  BMJ       Date:  2005-02-24

8.  [Long term management of childhood atopic dermatitis with calcineurin inhibitors].

Authors:  D Thaçi
Journal:  Hautarzt       Date:  2003-04-04       Impact factor: 0.751

Review 9.  Treatment of atopic dermatitis and impact on quality of life: a review with emphasis on topical non-corticosteroids.

Authors:  Roman Schiffner; Julia Schiffner-Rohe; Michael Landthaler; Wilhelm Stolz
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

10.  [Topical immunomodulators in dermatology].

Authors:  N Meykadeh; U R Hengge
Journal:  Hautarzt       Date:  2003-07       Impact factor: 0.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.